News
Archive: October 2025
Trading update for the year ended 30 September 2025
16 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced a trading update, pre-audit, for its financial year ended 30 September 2025 (“FY25”).
New blood based biomarker contract win and contract extension worth a total of £1.2 million
15 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract to assist in the validation of a diagnostic blood test, reaffirming the Company’s expertise in this area. IXICO has also entered into a contract extension on an existing Alzheimer’s Disease (AD) clinical trial. The combined value of the new contract and contract extension is c. £1.2 million.
IXICO wins "CRO Provider of the Year 2025" at the Precision Medicine Awards!
We’re proud to announce that IXICO has been named CRO Provider of the Year at the Precision Medicine Awards 2025, hosted by Oxford Global. This award celebrates our commitment to advancing precision in neuroscience through cutting-edge neuroimaging and AI-powered analytics.